Figure 2. Age-specific reactogenicity of CYD-TDV: proportion of participants by age and vaccine group with different categories of adverse events after each vaccination. Control group participants aged < 12 y at inclusion received intramuscular doses of hepatitis A vaccine and those aged ≥ 12 y received subcutaneous inactivated influenza vaccine.